VICTORIA, BC, July 8, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company's Chief Operating and Scientific Officer, Dr. Amanda Malone, will be presenting at the upcoming Controlled Release Society 2024 Annual Meeting and Expo being held in Bologna,